Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 3/20 | 0.58 |
| ▸ | MTNR1A | P48039 | 13/20 | 0.55 |
| ▸ | MTNR1B | P49286 | 3/20 | 0.52 |
| ▸ | HTR2C | P28335 | 1/20 | 0.52 |
| ▸ | HTR2B | P41595 | 1/20 | 0.52 |
| ▸ | NQO2 | P16083 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30449882 | 1.00 | HTR2A (0.58) | HTR2AMTNR1AMTNR1BHTR2CHTR2B | |
| SCHEMBL28070559 | 1.00 | HTR2A (0.58) | HTR2AMTNR1AMTNR1BHTR2CHTR2B | |
| SCHEMBL28852792 | 0.94 | HTR2A (0.53) | HTR2AMTNR1AMTNR1BHTR2CHTR2B | |
| SCHEMBL3147660 | 0.90 | HTR2A (0.48) | HTR2AMTNR1AMTNR1BHTR2CHTR2B | |
| SCHEMBL8933621 | 0.88 | MTNR1A (0.52) | MTNR1AMTNR1BNQO2 | |
| Trifluoromethanesulfonic Acid SCHEMBL28227878 | 0.87 | MTNR1A (0.53) | HTR2AMTNR1AMTNR1BHTR2CHTR2B | |
| SCHEMBL27784397 | 0.86 | HTR2A (0.45) | HTR2AMTNR1AMTNR1BHTR2CHTR2B | |
| SCHEMBL15662571 | 0.85 | MTNR1A (0.54) | HTR2AMTNR1AMTNR1B | |
| SCHEMBL14005971 | 0.85 | HTR2A (0.56) | HTR2AMTNR1AMTNR1BHTR2CHTR2B | |
| SCHEMBL8023255 | 0.85 | HTR2A (0.63) | HTR2AMTNR1AMTNR1BHTR2CHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 359 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119707714-A | Preparation method of 2- (7-methoxy-1-naphthyl) ethylamine hydrochloride | 苏州盛达药业有限公司 | 2025-03-28 | — | — | CN | claimed |
| CN-119462500-A | Preparation method of 7- (4-chlorobutoxy) -1H-quinolin-2-one | 湖南省湘中制药有限公司 | 2025-02-18 | — | — | CN | claimed |
| CN-117720424-B | Continuous flow preparation method of agomelatine intermediate | 江苏威奇达药业有限公司 | 2024-12-06 | — | — | CN | claimed |
| CN-118047686-A | Preparation method of N, N-di [2- (7-methoxy-1-naphthyl) ethyl ] amine impurity | 湖南九维生物医药有限公司 | 2024-05-17 | — | — | CN | claimed |
| CN-117776934-A | Preparation method of agomelatine intermediate | 江苏威奇达药业有限公司 | 2024-03-29 | — | — | CN | claimed |
| CN-117720424-A | Continuous flow preparation method of agomelatine intermediate | 江苏威奇达药业有限公司 | 2024-03-19 | — | — | CN | claimed |
| CN-117567321-A | Preparation method of 7-methoxy naphthalene acetonitrile | 湖南省湘中制药有限公司 | 2024-02-20 | — | — | CN | claimed |
| CN-113527139-A | Method for synthesizing 7-methoxy-1-naphthylacetonitrile and intermediate | 上海法默生物科技有限公司 | 2021-10-22 | — | — | CN | claimed |
| CN-112574066-A | Preparation method of agomelatine intermediate | 江苏豪森药业集团有限公司 | 2021-03-30 | — | — | CN | claimed |
| CN-111377829-A | Preparation method of 7-methoxy-1-naphthylacetonitrile | 苏州敬业医药化工有限公司 | 2020-07-07 | — | — | CN | claimed |
| WO-2014064706-A1 | PROCESSES FOR THE PREPARATION OF AGOMELATINE USING NOVEL INTERMEDIATES | SYMED LABS LIMITED (IN) | 2014-05-01 | — | — | WO | claimed |
| EP-2705023-A1 | PROCESSES FOR THE PREPARATION OF N-[2-(7-METHOXY-1-NAPHTHYL)ETHYL]ACETAMIDE | Symed Labs Limited (IN) | 2014-03-12 | — | — | EP | claimed |
| CN-103113243-A | Synthetic method of 2-(7-methoxyl-1-naphthyl) ethylamine hydrochloride | SHANDONG FANGMING PHARM GROUP | 2013-05-22 | — | — | CN | claimed |
| CN-101792400-B | Synthetic method for agomelatine | UNIV EAST CHINA NORMAL | 2013-01-30 | — | — | CN | claimed |
| EP-2151427-B1 | New method for synthesising agomelatine | SERVIER LAB (FR) | 2012-12-19 | — | — | EP | claimed |
| US-8329947-B2 | Process for the synthesis of agomelatine | LES LABORATOIRES SERVIER (FR) | 2012-12-11 | — | — | US | claimed |
| WO-2012093402-A1 | PROCESSES FOR THE PREPARATION OF N-[2-(7-METHOXY-1-NAPHTHYL)ETHYL]ACETAMIDE | SYMED LABS LIMITED (IN) | 2012-07-12 | — | — | WO | claimed |
| WO-2010015744-A1 | NOVEL PROCESS FOR THE SYNTHESIS OF AGOMELATINE | LES LABORATOIRES SERVIER (FR) | 2010-02-11 | — | — | WO | claimed |
| US-20100036161-A1 | Process for the synthesis of agomelatine | LES LABORATOIRES SERVIER (FR) | 2010-02-11 | — | — | US | claimed |
| EP-2151427-A1 | New method for synthesising agomelatine | Les Laboratoires Servier (FR) | 2010-02-10 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100036161-A1 | Process for the synthesis of agomelatine | COMT, PNMT, TPH1 | HTR2A 49/4885MTNR1A 331/4885MTNR1B 293/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.